Loading clinical trials...
Loading clinical trials...
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
Conditions
Interventions
Drug: Ivonescimab Injection
Drug: Bevacizumab Injection
Locations
54
United States
Clinical Study Site
Goodyear, Arizona, United States
Clinical Study Site
Beverly Hills, California, United States
Clinical Study Site
Cerritos, California, United States
Clinical Study Site
Corona, California, United States
Clinical Study Site
Duarte, California, United States
Clinical Study Site
Huntington Beach, California, United States
Start Date
November 18, 2025
Primary Completion Date
May 31, 2028
Completion Date
November 30, 2029
Last Updated
April 6, 2026
NCT07286695
NCT06944548
NCT04627142
Lead Sponsor
Summit Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions